Artificial Intelligence's Potential In Pharma Manufacturing

Join this webinar to explore how pharma companies can navigate the evolving regulatory landscape and harness the full potential of Stevanato Group’s AI technologies while staying ahead of FDA's cautious, risk-based approach to regulation.

New AI technologies hold tremendous potential for use in all areas of the pharma industry, but as the industry ventures into this uncharted territory, new regulatory considerations must be addressed. FDA Commissioner Robert Califf has communicated a desire to get ahead of regulating new disruptive technology and most anticipate that regulators will adopt a cautious yet risk-based approach. This webinar will explore how pharma companies can navigate this evolving regulatory landscape in order to make the most of AI technologies.